INS and polycystic ovary syndrome: Table 3 supports the identification of key biochemical pathways in PCOS, guiding phenotype-specific interventions, such as insulin-sensitizing therapies for Group D’s insulin resistance (HOMA-IR, QUICKI) and liver function monitoring for Group C.